Cargando…
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
OBJECTIVES: To show the levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with end-stage renal disease (ESRD) and to show the associations with clinical findings such as demographic features, laboratory findings, comorbi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Saudi Medical Journal
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058753/ https://www.ncbi.nlm.nih.gov/pubmed/29915853 http://dx.doi.org/10.15537/smj.2018.6.22024 |
_version_ | 1783341755998928896 |
---|---|
author | Erturk, Ismail Yesildal, Fatih Acar, Ramazan Ozgurtas, Taner Saglam, Kenan |
author_facet | Erturk, Ismail Yesildal, Fatih Acar, Ramazan Ozgurtas, Taner Saglam, Kenan |
author_sort | Erturk, Ismail |
collection | PubMed |
description | OBJECTIVES: To show the levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with end-stage renal disease (ESRD) and to show the associations with clinical findings such as demographic features, laboratory findings, comorbidities, and medications. METHODS: A total of 73 people, consisting of patients with ESRD (n=38) and healthy subjects (n=35) in Gulhane Education and Research Hospital, Ankara, Turkey, were included in this cross-sectional study between the years 2011 and 2013. Blood samples were obtained and plasma VEGF, sVEGFR-1 analyzes were performed. RESULTS: The VEGF level of ESRD group was not significantly higher (0.280±0.264) than the control group (0.321±0.210) (p=0.475). The sVEGFR-1 level of ESRD group was significantly higher (0.217±0.135) than the control group (0.068±0.047) (p<0.001). The correlation between VEGF and sVEGFR-1 was significant and negative (r=-0.246, p=0.036). Average VEGF level of ESRD patients using recombinant human erythropoietin (rhEPO) was significantly higher (0.567±0.28) than the ESRD patients not using rhEPO (0.246±0.24) (p=0.025). CONCLUSION: Our study is the first showing the significance of sVEGFR-1 in ESRD patients, and associations with comorbidities, medications. Especially our finding of rhEPO and VEGF may illuminate a reasonable positive effect of rhEPO on angiogenesis. Soluble vascular endothelial growth factor receptor-1 and VEGF may be important markers in the pathophysiology of ESRD. |
format | Online Article Text |
id | pubmed-6058753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Saudi Medical Journal |
record_format | MEDLINE/PubMed |
spelling | pubmed-60587532018-07-27 Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications Erturk, Ismail Yesildal, Fatih Acar, Ramazan Ozgurtas, Taner Saglam, Kenan Saudi Med J Original Article OBJECTIVES: To show the levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with end-stage renal disease (ESRD) and to show the associations with clinical findings such as demographic features, laboratory findings, comorbidities, and medications. METHODS: A total of 73 people, consisting of patients with ESRD (n=38) and healthy subjects (n=35) in Gulhane Education and Research Hospital, Ankara, Turkey, were included in this cross-sectional study between the years 2011 and 2013. Blood samples were obtained and plasma VEGF, sVEGFR-1 analyzes were performed. RESULTS: The VEGF level of ESRD group was not significantly higher (0.280±0.264) than the control group (0.321±0.210) (p=0.475). The sVEGFR-1 level of ESRD group was significantly higher (0.217±0.135) than the control group (0.068±0.047) (p<0.001). The correlation between VEGF and sVEGFR-1 was significant and negative (r=-0.246, p=0.036). Average VEGF level of ESRD patients using recombinant human erythropoietin (rhEPO) was significantly higher (0.567±0.28) than the ESRD patients not using rhEPO (0.246±0.24) (p=0.025). CONCLUSION: Our study is the first showing the significance of sVEGFR-1 in ESRD patients, and associations with comorbidities, medications. Especially our finding of rhEPO and VEGF may illuminate a reasonable positive effect of rhEPO on angiogenesis. Soluble vascular endothelial growth factor receptor-1 and VEGF may be important markers in the pathophysiology of ESRD. Saudi Medical Journal 2018-06 /pmc/articles/PMC6058753/ /pubmed/29915853 http://dx.doi.org/10.15537/smj.2018.6.22024 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Erturk, Ismail Yesildal, Fatih Acar, Ramazan Ozgurtas, Taner Saglam, Kenan Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications |
title | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications |
title_full | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications |
title_fullStr | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications |
title_full_unstemmed | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications |
title_short | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications |
title_sort | vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: associations with laboratory findings, comorbidities, and medications |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058753/ https://www.ncbi.nlm.nih.gov/pubmed/29915853 http://dx.doi.org/10.15537/smj.2018.6.22024 |
work_keys_str_mv | AT erturkismail vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications AT yesildalfatih vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications AT acarramazan vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications AT ozgurtastaner vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications AT saglamkenan vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications |